Daclizumab can cause unpredictable and potentially fatal immune-mediated liver injury. Several cases of serious liver injury including immune-mediated hepatitis and fulminant liver injury have been reported.
Healthcare professionals are advised a range of measures to minimise risks; Please follow link for further details.